CClinicalTrials.gg
CompletedNCT03245463Updated Nov 5, 2019Results posted

Evaluation of Methods of Teaching Self-management Strategies to Patients With Symptomatic Knee Osteoarthritis

A Phase 4 interventional study of Educational handout and Verbal script in Osteoarthritis, Knee, sponsored by Hospital for Special Surgery, New York. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-05.

Sponsored by Hospital for Special Surgery, New York · Phase 4, Interventional, and Other

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Symptomatic knee osteoarthritis greatly impacts the quality of life, mobility, independence, and even safety of the individuals who suffer from it. One of the most powerful tools for these patients can be education on self-care and self-management strategies that can be taught to a patient by a physician, physical or occupational therapist, or a nurse. These self-management strategies can help patients treat daily stiffness through exercise or manage flares of osteoarthritis. There is a lack of consensus on the best teaching methods to accomplish the goal of educating our patients. Feedback from both patients and providers regarding teaching methods is needed. This study will evaluate teaching methods on self-management strategies for patients who are undergoing hyaluronic acid injections for knee osteoarthritis.

02

Conditions studied

  • Osteoarthritis, Knee
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 583 are open to participants now.

This study's enrollment of 24 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Hospital for Special Surgery, New York is the lead sponsor of 217 studies on the registry; 39 are open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 20 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients of co-investigator physicians
  • Age 18+ years
  • Diagnosis of symptomatic knee osteoarthritis
  • Scheduled for a hyaluronic acid injection into the knee
  • Provider is available to administer teaching method

Exclusion criteria

Exclusion Criteria:

  • Patients who are already enrolled in the study
  • Non-English speaking
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Teaching Method A

    Patient will receive an educational handout on self-management strategies. Patient will be asked to take the handout home to read and to call the office if he/she has any questions.

    Other: Educational handout · Drug: Hyaluronic Acid

  • Active comparator
    Teaching Method B

    Patient will receive an educational handout on self-management strategies. A provider will review the handout with the patient (approximately 5 minutes including a question-and-answer session).

    Other: Educational handout · Other: Verbal script · Drug: Hyaluronic Acid

Interventions

  • OtherEducational handout

    The educational handout will include information on self-management strategies.

  • OtherVerbal script

    The verbal script will include details on self-management strategies that will be reviewed with the patient.

  • DrugHyaluronic Acid

    All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.

06

What researchers measure

Primary outcomes

  1. Patient Satisfaction With the Teaching Method

    Satisfaction will be assessed using a 0-10 scale, where 0=not satisfied and 10=most satisfied. The higher the score, the greater the satisfaction.

    Time frame: 1 month post-injection

  2. Provider Satisfaction With the Teaching Method

    Satisfaction will be assessed using a 0-10 scale, where 0=not satisfied and 10=most satisfied. The higher the score, the greater the satisfaction.

    Time frame: 1 month post-injection

  3. Patient Satisfaction With the Teaching Method

    Satisfaction will be assessed using a 0-10 scale, where 0=not satisfied and 10=most satisfied. The higher the score, the greater the satisfaction.

    Time frame: 3 months post-injection

Secondary outcomes

  1. Number of Patients Who Would Have Preferred a Different Method of Receiving Education.

    Patient will be asked: "Would you have preferred a different method of receiving education?"

    Time frame: 3 months post-injection

  2. Number of Patients Who Believed That the Education They Received Helped With the Care of Their Osteoarthritis

    Patient will be asked: "Did the education you received help with the care of your osteoarthritis?"

    Time frame: 3 months post-injection

  3. PROMIS Physical Health Score

    The physical health score will be surveyed using the PROMIS-10 global health questionnaire. A higher score indicates better physical health. Scores range from 16.2 to 67.7.

    Time frame: 3 months post-injection

07

Results

Posted Nov 5, 2019

Participant flow

Participant flow — Overall Study
MilestoneTeaching Method ATeaching Method B
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryPatient Satisfaction With the Teaching Method

Satisfaction will be assessed using a 0-10 scale, where 0=not satisfied and 10=most satisfied. The higher the score, the greater the satisfaction.

Time frame:
1 month post-injection
Reported as:
Mean · units on a scale
Patient Satisfaction With the Teaching Method
units on a scaleTeaching Method ATeaching Method B
Patient Satisfaction With the Teaching Method8.8 ± 1.68.3 ± 2.2
PrimaryProvider Satisfaction With the Teaching Method

Satisfaction will be assessed using a 0-10 scale, where 0=not satisfied and 10=most satisfied. The higher the score, the greater the satisfaction.

Time frame:
1 month post-injection
Reported as:
Mean · units on a scale
Provider Satisfaction With the Teaching Method
units on a scaleTeaching Method ATeaching Method B
Provider Satisfaction With the Teaching Method6.0 ± 1.98.0 ± 1.0
PrimaryPatient Satisfaction With the Teaching Method

Satisfaction will be assessed using a 0-10 scale, where 0=not satisfied and 10=most satisfied. The higher the score, the greater the satisfaction.

Time frame:
3 months post-injection
Reported as:
Mean · units on a scale
Patient Satisfaction With the Teaching Method
units on a scaleTeaching Method ATeaching Method B
Patient Satisfaction With the Teaching Method8.6 ± 2.28.6 ± 1.0
SecondaryNumber of Patients Who Would Have Preferred a Different Method of Receiving Education.

Patient will be asked: "Would you have preferred a different method of receiving education?"

Time frame:
3 months post-injection
Reported as:
Count of participants · Participants
Number of Patients Who Would Have Preferred a Different Method of Receiving Education.
ParticipantsTeaching Method ATeaching Method B
Number of Patients Who Would Have Preferred a Different Method of Receiving Education.11
SecondaryNumber of Patients Who Believed That the Education They Received Helped With the Care of Their Osteoarthritis

Patient will be asked: "Did the education you received help with the care of your osteoarthritis?"

Time frame:
3 months post-injection
Reported as:
Count of participants · Participants
Number of Patients Who Believed That the Education They Received Helped With the Care of Their Osteoarthritis
ParticipantsTeaching Method ATeaching Method B
Number of Patients Who Believed That the Education They Received Helped With the Care of Their Osteoarthritis78
SecondaryPROMIS Physical Health Score

The physical health score will be surveyed using the PROMIS-10 global health questionnaire. A higher score indicates better physical health. Scores range from 16.2 to 67.7.

Time frame:
3 months post-injection
Reported as:
Mean · score on a scale
PROMIS Physical Health Score
score on a scaleTeaching Method ATeaching Method B
PROMIS Physical Health Score45.8 ± 5.148.4 ± 6.5

Adverse events

Collected over Adverse event data were collected over 3 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teaching Method A0/12 (0%)0/12 (0%)0/12 (0%)
Teaching Method B0/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Teaching Method ATeaching Method BTotal
Mean71 ± 869 ± 1370 ± 10
Sex: Female, Male
Sex: Female, Male(Participants)Teaching Method ATeaching Method BTotal
Female81018
Male426
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Teaching Method ATeaching Method BTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White11920
More than one race000
Unknown or Not Reported134
Region of Enrollment
Region of Enrollment(participants)Teaching Method ATeaching Method BTotal
United States121224
Average pain
Average pain(units on a 0-10 scale)Teaching Method ATeaching Method BTotal
Mean5.6 ± 2.24.8 ± 2.35.2 ± 2.2
08

Study locations

1 site
  • Hospital for Special Surgery
    New York, New York 10021, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jul 25, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03245463
Lead sponsor
Hospital for Special Surgery, New York
Responsible party
Sponsor
First posted
Aug 10, 2017
Start date
Aug 9, 2017
Primary completion
Feb 13, 2018
Completion
Feb 13, 2018
Results posted
Nov 5, 2019
Last update
Nov 5, 2019

Study contacts

James Wyss, MD
principal investigator · Hospital for Special Surgery, New York

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion